A

fter months of urging from Wall Street, Gilead Sciences (GILD) finally made a big acquisition — paying nearly $12 billion in cash to buy Kite Pharmaceuticals (KITE), a leader in developing so-called CAR-T therapies that leverage the body’s own immune system to fight cancer.

For Gilead, the move is a way to quickly diversify beyond its infectious-disease franchise. Although its HIV portfolio remains dominant, declining sales of its hepatitis C drugs have hurt its stock price. Moreover, this may finally help Gilead dive into the lucrative cancer market, where the company has suffered several notable setbacks.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Ah, and so in another drive for innovation, Gilead re-defines ‘Kite’-ing a check into something ostensibly positive. Time will tell if it ‘bounce$’ or not.